

November 11, 2016
Symbio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Notice Concerning Non-operating Expenses

Symbio Pharmaceuticals Limited (“the Company”) announces accrued non-operating expenses for the third quarter of the fiscal year ended December 31, 2016 (from July 1, 2016 to September 30, 2016).

1. Details of Non-operating Expenses

The Company recorded a foreign exchange loss of 25,646 thousand yen under non-operating expenses for the third quarter of the fiscal year ended December 31, 2016 (from July 1, 2016 to September 30, 2016) due to recent fluctuations in foreign exchange rates. In addition, with a foreign exchange loss of 330,411 thousand yen for the three months ended June 30, 2016, a total foreign exchange loss of 356,057 thousand yen was recorded as statements of operations for the third quarter of the fiscal year ended December 31, 2016.

2. Future Outlook

Based on its assumption concerning operational trends for this fiscal year, the Company determined that these non-operating expenses would have no significant impact on the results of operations for the year with no modification to the financial forecast required. The Company will make a prompt announcement should any modification to the financial forecast be necessary.

[Contact]

Investor Relations
Tel: +81(0)3 5472 1125